Skip to main content
Premium Trial:

Request an Annual Quote

BioTrove to Market Sample Prep System with Agilent Mass Spec Tools

NEW YORK (GenomeWeb News) – BioTrove will sell its sample preparation system with Agilent’s mass spectrometers as integrated systems under a new reseller agreement, BioTrove said today.
Under the non-exclusive agreement, which expands one signed a year ago, BioTrove will offer an end-to-end mass spec analysis solution aimed at the drug development market.
The agreement covers BioTrove’s RapidFire system, which includes robotics and microfluidic handling for sample prep and software, as an integrated solution with Agilent’s triple quadrupole and time-of-flight mass spectrometers. It also includes Agilent’s atmospheric pressure ionization sources.
The global agreement allows BioTrove to offer Agilent’s 6410 and 6460 Triple Quadrupole LC/MS systems, and its 6220 Accurate Mass Time-of-Flight system.
Gus Salem, Agilent's general manager of LC/MS, said the partnership “will enable unique, label-free assays that were previously virtually impossible.”
The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.